-- Intel (INTC) has an average rating of hold and mean price target of $67.72, according to analysts polled by FactSet.
(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)
Price: $83.18, Change: $+16.40, Percent Change: +24.56%
NiSource Inc (NI) has an average rating of overweight and mean price target of $51, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)Price: $48.10, Change: $-0.19, Percent Change: -0.39%
Air Canada (AC.TO) received the first of 30 Airbus A321XLR aircraft it ordered, the airline said on Friday.The aircraft, leased from SMBC Aviation Capital, has a range of up to 4,700 nautical miles and with 30% lower fuel burn per seat. It is also able to operate with up to 50% Sustainable Aviation Fuel (SAF), a statement said.This flying range allows Air Canada to operate non-stop transatlantic flights from Montreal and Toronto to destinations such as Berlin, Toulouse and Edinburgh.Air Canada currently operates a fleet of 136 Airbus aircraft and has 61 aircraft on order, including recently ordered A350 aircraft.Air Canada shares were last seen up $0.10 to $18.36 on the Toronto Stock Exchange.Price: $18.35, Change: $+0.09, Percent Change: +0.49%
Bausch + Lomb's (BLCO) Q1 likely saw revenue tailwinds from foreign exchange, continuing trends from Q4, RBC Capital Markets said in a Thursday note.Broad currency strength, compared with the US dollar, is estimated to have yielded about a $40 million revenue benefit in Q1 and will likely add about $70 million for all of 2026, RBC said. The company's 2026 revenue guidance currently calls for a $30 million FX tailwind, RBC said.Bausch + Lomb is set to report its Q1 results on April 29 and investors are expected to focus on the company's primary prescription for dry eye disease products, the investment firm added. RBC said investor concerns include Miebo's profitability in 2026 and Xiidra's net pricing improvement.RBC has an outperform rating on Bausch + Lomb, with a $21 price target.Price: $15.75, Change: $-0.03, Percent Change: -0.19%